The spectrum of antiviral activities of acyclovir in vitro and in vivo.
In vitro sensitivity data suggest that acyclovir should be effective against clinical manifestations of herpes simplex virus types 1 and 2, varicella-zoster virus and possibly Epstein-Barr virus. The clinical potential against herpes simplex virus types 1 and 2 is further supported by results in animal models. Human cytomegalovirus and the veterinary herpes viruses, with the possible exception of equine herpes virus type 1, may be insufficiently sensitive to be amenable to treatment.
D000212:Acyclovir / Q000494:pharmacology*; D000818:Animals; D003587:Cytomegalovirus / Q000187:drug effects; D004660:Encephalitis / Q000188:drug therapy; D006168:Guinea Pigs; D006515:Hepatitis B virus / Q000187:drug effects; D006561:Herpes Simplex / Q000188:drug therapy*; D006568:Herpesvirus 1, Cercopithecine / Q000187:drug effects; D014645:Herpesvirus 3, Human / Q000187:drug effects; D004854:Herpesvirus 4, Human / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007635:Keratitis, Dendritic / Q000188:drug therapy; D051379:Mice; D011817:Rabbits; D012008:Recurrence; D018139:Simplexvirus / Q000187:drug effects*
D000212:Acyclovir